Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

Related News

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Content from other channels on our network

AMCRC announces project to evaluate local titanium powder

NSW to invest $12bn to rebuild Hunter train manufacturing

Orica hydrogen hub project reaches major investment milestone

Dual-bubble method removes more microplastics from wastewater

Energy crisis will have long‍-‍term effects: Australian Industry Group

Sydney University signs agrifood innovation agreement with FAO

interpack 2029 will have a new runtime

Jet Technologies partners with coffee processing specialist Neuhaus Neotec

Arla Foods acquires Aussie cottage cheese producer

Ferrero appoints new GM to lead Australia and NZ

Microbubbles remove microplastics from wastewater

Partnership boosts bio-based graphite material deployment

New way to recycle coloured plastics using silica microspheres

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

  • All content Copyright © 2026 Westwick-Farrow Pty Ltd